164 related articles for article (PubMed ID: 38003399)
1. Comparison between [
Brighi C; Puttick S; Woods A; Keall P; Tooney PA; Waddington DEJ; Sproule V; Rose S; Fay M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003399
[TBL] [Abstract][Full Text] [Related]
2. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.
Lohmann P; Stavrinou P; Lipke K; Bauer EK; Ceccon G; Werner JM; Neumaier B; Fink GR; Shah NJ; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):591-602. PubMed ID: 30327856
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
[TBL] [Abstract][Full Text] [Related]
4. [
Koh ES; Gan HK; Senko C; Francis RJ; Ebert M; Lee ST; Lau E; Khasraw M; Nowak AK; Bailey DL; Moffat BA; Fitt G; Hicks RJ; Coffey R; Verhaak R; Walsh KM; Barnes EH; De Abreu Lourenco R; Rosenthal M; Adda L; Foroudi F; Lasocki A; Moore A; Thomas PA; Roach P; Back M; Leonard R; Scott AM
BMJ Open; 2023 Aug; 13(8):e071327. PubMed ID: 37541751
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.
Sasikumar A; Joy A; Pillai MR; Nanabala R; Anees K M; Jayaprakash PG; Madhavan J; Nair S
Clin Nucl Med; 2017 Jan; 42(1):e41-e48. PubMed ID: 27846000
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
8. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
[TBL] [Abstract][Full Text] [Related]
9. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
10. Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.
Barry N; Francis RJ; Ebert MA; Koh ES; Rowshanfarzad P; Hassan GM; Kendrick J; Gan HK; Lee ST; Lau E; Moffat BA; Fitt G; Moore A; Thomas P; Pattison DA; Akhurst T; Alipour R; Thomas EL; Hsiao E; Schembri GP; Lin P; Ly T; Yap J; Kirkwood I; Vallat W; Khan S; Krishna D; Ngai S; Yu C; Beuzeville S; Yeow TC; Bailey D; Cook O; Whitehead A; Dykyj R; Rossi A; Grose A; Scott AM
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3970-3981. PubMed ID: 37563351
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [
Henriksen OM; Hansen AE; Muhic A; Marner L; Madsen K; Møller S; Hasselbalch B; Lundemann MJ; Scheie D; Skjøth-Rasmussen J; Poulsen HS; Larsen VA; Larsson HBW; Law I
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4677-4691. PubMed ID: 35907033
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma PET/MRI: kinetic investigation of [
Lindemann M; Oteiza A; Martin-Armas M; Guttormsen Y; Moldes-Anaya A; Berzaghi R; Bogsrud TV; Bach-Gansmo T; Sundset R; Kranz M
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1183-1194. PubMed ID: 36416908
[TBL] [Abstract][Full Text] [Related]
13. Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo.
Kumar A; ArunRaj ST; Bhullar K; Haresh KP; Gupta S; Ballal S; Yadav M; Singh M; Damle NA; Garg A; Tripathi M; Bal C
Neuroradiology; 2022 May; 64(5):969-979. PubMed ID: 34648046
[TBL] [Abstract][Full Text] [Related]
14. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer.
Al Jalali V; Wasinger G; Rasul S; Grubmüller B; Wulkersdorfer B; Balber T; Mitterhauser M; Simon J; Hacker M; Shariat S; Egger G; Zeitlinger M
J Nucl Med; 2023 Jun; 64(6):863-868. PubMed ID: 36657982
[TBL] [Abstract][Full Text] [Related]
15. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
16. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Dynamic O-(2-[
Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative tissue fluorescence using 5-aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography ((18)F-FET PET) in glioblastoma surgery.
Roessler K; Becherer A; Donat M; Cejna M; Zachenhofer I
Neurol Res; 2012 Apr; 34(3):314-7. PubMed ID: 22449387
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?
Piroth MD; Liebenstund S; Galldiks N; Stoffels G; Shah NJ; Eble MJ; Coenen HH; Langen KJ
Mol Imaging; 2013 Sep; 12(6):388-95. PubMed ID: 23981784
[TBL] [Abstract][Full Text] [Related]
20. (18)F-Fluoroethyl-l-Thyrosine Positron Emission Tomography to Delineate Tumor Residuals After Glioblastoma Resection: A Comparison with Standard Postoperative Magnetic Resonance Imaging.
Buchmann N; Kläsner B; Gempt J; Bauer JS; Pyka T; Delbridge C; Meyer B; Krause BJ; Ringel F
World Neurosurg; 2016 May; 89():420-6. PubMed ID: 26893043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
